KR20200092946A - 결정질 리나글립틴 중간체 및 리나글립틴 제조 공정 - Google Patents

결정질 리나글립틴 중간체 및 리나글립틴 제조 공정 Download PDF

Info

Publication number
KR20200092946A
KR20200092946A KR1020207012196A KR20207012196A KR20200092946A KR 20200092946 A KR20200092946 A KR 20200092946A KR 1020207012196 A KR1020207012196 A KR 1020207012196A KR 20207012196 A KR20207012196 A KR 20207012196A KR 20200092946 A KR20200092946 A KR 20200092946A
Authority
KR
South Korea
Prior art keywords
formula
linagliptin
crystalline form
reaction
linagliptin intermediate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207012196A
Other languages
English (en)
Korean (ko)
Inventor
벤카타 라가벤드라찰유루 팔레
샨무가사미 라즈마헨드라
달샨 작카리 찬드레고우다
탄가라수 폰너사미
Original Assignee
바이오콘 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오콘 리미티드 filed Critical 바이오콘 리미티드
Publication of KR20200092946A publication Critical patent/KR20200092946A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020207012196A 2017-09-27 2018-09-27 결정질 리나글립틴 중간체 및 리나글립틴 제조 공정 Ceased KR20200092946A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201741034292 2017-09-27
IN201741034292 2017-09-27
PCT/IB2018/057484 WO2019064214A1 (en) 2017-09-27 2018-09-27 INTERMEDIATE OF CRYSTALLINE LINAGLIPTIN AND PROCESS FOR THE PREPARATION OF LINAGLIPTIN

Publications (1)

Publication Number Publication Date
KR20200092946A true KR20200092946A (ko) 2020-08-04

Family

ID=65903063

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207012196A Ceased KR20200092946A (ko) 2017-09-27 2018-09-27 결정질 리나글립틴 중간체 및 리나글립틴 제조 공정

Country Status (10)

Country Link
US (1) US11040974B2 (cg-RX-API-DMAC7.html)
JP (1) JP2020535193A (cg-RX-API-DMAC7.html)
KR (1) KR20200092946A (cg-RX-API-DMAC7.html)
CN (1) CN111511743A (cg-RX-API-DMAC7.html)
AU (1) AU2018343236A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020005964A2 (cg-RX-API-DMAC7.html)
CA (1) CA3076980A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020004050A (cg-RX-API-DMAC7.html)
RU (1) RU2020114890A (cg-RX-API-DMAC7.html)
WO (1) WO2019064214A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110684026A (zh) * 2019-10-24 2020-01-14 扬子江药业集团上海海尼药业有限公司 一种利格列汀的工业化制备方法
CN110872292B (zh) * 2019-11-30 2022-01-25 江苏君若药业有限公司 一条合成糖尿病药物利拉利汀的路线
EP4349837A1 (en) 2022-10-05 2024-04-10 Zaklady Farmaceutyczne "Polpharma" S.A. A pharmaceutical intermediate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
IN2013MU02055A (cg-RX-API-DMAC7.html) * 2013-06-18 2015-07-03 Cadila Healthcare Ltd
WO2015011609A1 (en) * 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Process for the preparation of linagliptin and an intermediate thereof

Also Published As

Publication number Publication date
JP2020535193A (ja) 2020-12-03
BR112020005964A2 (pt) 2020-10-06
WO2019064214A1 (en) 2019-04-04
US11040974B2 (en) 2021-06-22
US20200354363A1 (en) 2020-11-12
RU2020114890A (ru) 2021-10-27
CA3076980A1 (en) 2019-04-04
CN111511743A (zh) 2020-08-07
MX2020004050A (es) 2020-11-06
AU2018343236A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
KR102810009B1 (ko) 고체 형태의 fgfr 억제제 화합물 및 그 제조방법
TWI585088B (zh) 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
US9056112B2 (en) Process for preparation of pure linagliptin
JP2019518776A (ja) Egfr阻害剤としてのアニリンピリミジン化合物の結晶
EP2985277A1 (en) Dipyrromethene crystal and method for manufacturing same
WO2017125097A1 (en) Crystalline forms of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4- yl)pyrazol-l-yl]propanenitrile salts and preparation thereof
US12084454B2 (en) Process for preparing BTK inhibitors
EP4732838A2 (en) Pharmaceutically acceptable salt and crystalline form of glp-1 receptor agonist and preparation method therefor
US20240217977A1 (en) Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
US11040974B2 (en) Crystalline linagliptin intermediate and process for preparation of linagliptin
EP3322709B1 (en) Crystalline forms of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile salts and preparation thereof
CZ2014502A3 (cs) Nová forma sofosbuviru a způsob její přípravy
US20090054424A1 (en) Optically active pyridine derivative and a medicament containing the same
EP3919479B1 (en) Compound having benzo seven-membered ring structure, preparation method therefor, and use thereof
EP3321267A1 (en) Crystalline forms of 2-[1-ethylsulfonyl-3-[7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile salts and preparation thereof
CN114685520B (zh) 三并环化合物及其药物组合物和应用
CN113227096A (zh) 1,2,3-三氮唑并[1,5-a]吡嗪类衍生物的晶型及其制备方法
EP1950206A1 (en) Benzoxazocines and their use as monoamine-reuptake inhibitors
US11827614B2 (en) Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates
KR20200092945A (ko) 레날리도마이드의 결정형
EP4644374A1 (en) Naphthylamide compound, and preparation method therefor and use thereof
US20230034132A1 (en) Crystal form as inhibitor of acc1 and acc2, and preparation method therefor and use thereof
WO2026017823A1 (en) Process for preparing btk inhibitor intermediates
EP4592286A1 (en) Macrocyclic nitrogen-containing crown ether compound and use thereof as protein kinase inhibitor
HK40060005A (en) Crystal form of 1,2,3-triazolo[1,5-a]pyrazines derivative and preparation method therefor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200427

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210901

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231006

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240102

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231006

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I